<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334061</url>
  </required_header>
  <id_info>
    <org_study_id>CLP 0676</org_study_id>
    <nct_id>NCT00334061</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Effectiveness of the Penumbra System</brief_title>
  <official_title>Evaluation of the Penumbra™ Stroke System in the Revascularization of Patients With Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical evaluation is a prospective, single-arm, multi-center trial.

      The purpose of this clinical evaluation is to assess the safety and effectiveness of the
      Penumbra System in the revascularization of patients presenting with acute ischemic stroke
      secondary to intracranial, large vessel, occlusive disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      The purpose of this clinical evaluation is to assess the safety and effectiveness of the
      Penumbra System in the revascularization of patients presenting with acute ischemic stroke
      secondary to intracranial, large vessel, occlusive disease. Up to 125 evaluable patients will
      be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Revascularization of the Occluded Target Vessel</measure>
    <time_frame>3-Month Post-Procedure</time_frame>
    <description>Revascularization is defined by a Thrombolysis in Myocardial Infarction (TIMI) score of 2 or 3 following use of the Penumbra System.
TIMI scores are used to describe blood flow at the treated vessel with 0 designating no flow and 3 for normal flow.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Device-related and Procedure-related Serious Adverse Events</measure>
    <time_frame>3-Month Post-Procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Either a 4-point Improvement on the National Institutes of Health Stroke Scale (NIHSS) at Discharge or a Modified Rankin Scale (mRS) Score of ≤ 2 at 30 Days After Treatment</measure>
    <time_frame>Discharge or 30-Days Post-Procedure</time_frame>
    <description>NIHSS is a 42 point scale to describe the neurological status of the patients:
0=no stroke; 1-15=minor to moderate stroke; 15-20=moderate/severe stroke; 21-42=severe stroke. The mRS is a scale to determine the activities of daily living of the patient with a score of 0 designating normal activities to a score of 6 designating death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Modified Rankin Scale (mRS) Score of ≤ 2 at 90 Days Post Treatment</measure>
    <time_frame>90-Day</time_frame>
    <description>The mRS is a scale to determine the activities of daily living of the patient with a score of 0 designating normal activities to a score of 6 designating death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All Cause Mortality</measure>
    <time_frame>90-Days Post-Treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Symptomatic Hemorrhage</measure>
    <time_frame>24-Hour Post-Procedure</time_frame>
    <description>All treated patients were scanned by computed tomography (CT) at 24-hours post-procedure to detect the presence of intracranial hemorrhage.</description>
  </secondary_outcome>
  <enrollment type="Actual">125</enrollment>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Penumbra System</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs consistent with acute ischemic stroke

          -  18 to 79 years of age

          -  Neurological deficit resulting in an NIH Stroke Scale (NIHSS) score &gt; 8

          -  TIMI 0 or TIMI I flow in vessels accessible to the Penumbra System

          -  Signed informed consent

          -  Present within 8 hours of stroke symptom onset; ineligible or refractory to
             intravenous tissue plasminogen activator (t-PA) therapy if presenting within 3 hours
             of symptom onset.

        Exclusion Criteria:

          -  Evidence of rapidly improving neurological signs of stroke at time of enrollment

          -  NIHSS &gt; 30 or coma

          -  Females who are pregnant

          -  Vessel tortuosity too difficult to allow endovascular access

          -  Known hemorrhagic diathesis, coagulation deficiency, or on oral anticoagulant therapy
             with an International Normalized Ratio (INR) &gt; 3.0

          -  Partial thromboplastin time (PTT) greater than 2 times the lab normal

          -  Admission platelets &lt; 30,000

          -  Pre-existing neurological or psychiatric disease that could confound the study results

          -  Known severe allergy to contrast media

          -  Uncontrolled hypertension

          -  Computed tomography (CT) evidence of significant mass effect with a midline shift

          -  CT reveals evidence of large hypodensity region &gt; 1/3 of the middle cerebral artery
             territory

          -  CT reveals evidence of intracranial hemorrhage

          -  CT reveals significant mass effect with midline shift

          -  Angiographic evidence of an arterial stenosis proximal to the occlusion that could
             prevent thrombus removal

          -  Angiographic evidence of preexisting arterial injury

          -  Life expectancy of less than 90 days

          -  Participation in another clinical investigation that could confound the evaluation of
             the study device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.penumbrainc.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 2, 2006</study_first_submitted>
  <study_first_submitted_qc>June 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2006</study_first_posted>
  <results_first_submitted>November 20, 2008</results_first_submitted>
  <results_first_submitted_qc>January 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2009</results_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <keyword>Penumbra</keyword>
  <keyword>Ischemic</keyword>
  <keyword>Stroke</keyword>
  <keyword>Intervention</keyword>
  <keyword>Neurovascular</keyword>
  <keyword>Thrombus</keyword>
  <keyword>Embolectomy</keyword>
  <keyword>Ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From June 19, 2006 to June 5, 2007 a total of 856 patients were screened of which 125 patients were enrolled at 24 centers in Europe and the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Penumbra System</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125">June 2006</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125">November 2007</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Penumbra System</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Revascularization of the Occluded Target Vessel</title>
        <description>Revascularization is defined by a Thrombolysis in Myocardial Infarction (TIMI) score of 2 or 3 following use of the Penumbra System.
TIMI scores are used to describe blood flow at the treated vessel with 0 designating no flow and 3 for normal flow.</description>
        <time_frame>3-Month Post-Procedure</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Revascularization of the Occluded Target Vessel</title>
          <description>Revascularization is defined by a Thrombolysis in Myocardial Infarction (TIMI) score of 2 or 3 following use of the Penumbra System.
TIMI scores are used to describe blood flow at the treated vessel with 0 designating no flow and 3 for normal flow.</description>
          <population>Intention to Treat</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Device-related and Procedure-related Serious Adverse Events</title>
        <time_frame>3-Month Post-Procedure</time_frame>
        <population>All adverse events were summarized by showing the number and percent of patients who reported the event. Events were also reported by relationship to the procedure or device. Causality of adverse events was adjudicated by a Clinical Events Committee. The denominator for the analyses was all enrolled patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Device-related and Procedure-related Serious Adverse Events</title>
          <population>All adverse events were summarized by showing the number and percent of patients who reported the event. Events were also reported by relationship to the procedure or device. Causality of adverse events was adjudicated by a Clinical Events Committee. The denominator for the analyses was all enrolled patients.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Either a 4-point Improvement on the National Institutes of Health Stroke Scale (NIHSS) at Discharge or a Modified Rankin Scale (mRS) Score of ≤ 2 at 30 Days After Treatment</title>
        <description>NIHSS is a 42 point scale to describe the neurological status of the patients:
0=no stroke; 1-15=minor to moderate stroke; 15-20=moderate/severe stroke; 21-42=severe stroke. The mRS is a scale to determine the activities of daily living of the patient with a score of 0 designating normal activities to a score of 6 designating death.</description>
        <time_frame>Discharge or 30-Days Post-Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Either a 4-point Improvement on the National Institutes of Health Stroke Scale (NIHSS) at Discharge or a Modified Rankin Scale (mRS) Score of ≤ 2 at 30 Days After Treatment</title>
          <description>NIHSS is a 42 point scale to describe the neurological status of the patients:
0=no stroke; 1-15=minor to moderate stroke; 15-20=moderate/severe stroke; 21-42=severe stroke. The mRS is a scale to determine the activities of daily living of the patient with a score of 0 designating normal activities to a score of 6 designating death.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Modified Rankin Scale (mRS) Score of ≤ 2 at 90 Days Post Treatment</title>
        <description>The mRS is a scale to determine the activities of daily living of the patient with a score of 0 designating normal activities to a score of 6 designating death.</description>
        <time_frame>90-Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Modified Rankin Scale (mRS) Score of ≤ 2 at 90 Days Post Treatment</title>
          <description>The mRS is a scale to determine the activities of daily living of the patient with a score of 0 designating normal activities to a score of 6 designating death.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All Cause Mortality</title>
        <time_frame>90-Days Post-Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All Cause Mortality</title>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Symptomatic Hemorrhage</title>
        <description>All treated patients were scanned by computed tomography (CT) at 24-hours post-procedure to detect the presence of intracranial hemorrhage.</description>
        <time_frame>24-Hour Post-Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Penumbra System</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Symptomatic Hemorrhage</title>
          <description>All treated patients were scanned by computed tomography (CT) at 24-hours post-procedure to detect the presence of intracranial hemorrhage.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Penumbra System</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Edema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Intracerebral Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Worsening Symptoms of Qualifying Stroke</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Stroke in New Territory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction/Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Dysfunction/Failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Other Pulmonary Complications</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Access Site Complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Vascular Complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cardiac Complications</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hepato-Biliary Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cerebral Edema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Worsening Symptoms of Qualifying Stroke</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Dysphasia-Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction/Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Pulmonary Complications</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Complication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Peripheral Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Embolization of Previously Uninvolved Vessel</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Siu Po Sit, PhD Study Coordinator</name_or_title>
      <organization>Penumbra Inc</organization>
      <phone>510 748 3200 ext 221</phone>
      <email>siupo.sit@penumbrainc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

